NCT07624305ClinicalTrials.gov
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)
A Phase III, Randomised, Double-blind, Study to Evaluate the Effect of Balcinrenone/Dapagliflozin Compared With Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Chronic Kidney Disease (Stage 3b and 4)
Kurz gefasst
The purpose of this study is to evaluate the efficacy, safety and tolerability of balcinrenone in fixed combination with dapagliflozin, compared with dapagliflozin, in patients with CKD Stage 3b and 4 (eGFR ≥ 15 to \< 45 mL/min/1.73 m2) administered…
Phase 32.800 Teilnehmende gesucht478 Studienzentren27 Länder
Kategorien
In 1 Register registriert
- ClinicalTrials.govNCT07624305Diesen Eintrag bei ClinicalTrials.gov öffnenSynchronisiert vor 2 Monaten
Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.
Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.
Interesse an dieser Studie?
Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-06-03; recorded start 2026-09-01
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 1038 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm15/15
Active-comparator control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type10/10
Mortality / MACE endpoint (hard clinical outcome)
- Multi-centre8/8
Multi-centre: 45 sites
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A large study, international in scope: 2,800 participants (target), run at 478 sites, across 27 countries.
How this score is built
- Enrolment34/40
2,800 participants (target)
- Site count19/25
45 sites
- Country count12/15
8 countries
- Planned duration9/10
Planned over about 47 months
- Sponsor scale10/10
AstraZeneca has led 999 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Zusammenfassung
The purpose of this study is to evaluate the efficacy, safety and tolerability of balcinrenone in fixed combination with dapagliflozin, compared with dapagliflozin, in patients with CKD Stage 3b and 4 (eGFR ≥ 15 to \< 45 mL/min/1.73 m2) administered orally once daily in addition to SoC. This is a population with high unmet medical need and an increased risk of CKD progression, who are frequently excluded from interventional trials.
Erkrankungen
- Renal Insufficiency, Chronic
Eignung
| Geschlecht | Alle |
|---|---|
| Alter | 18 Years – 99 Years |
| Gesunde Freiwillige | Nein |
Eignung im Wortlaut des Registers
Eignung in einfachen Aussagen
Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.
Studiendesign
| Studientyp | Interventionell |
|---|---|
| Phase | Phase 3 |
| Zuteilung | Randomisiert |
| Interventionsmodell | PARALLEL |
| Primäres Ziel | TREATMENT |
| Verblindung | QUADRUPLE (4) |
| Teilnahme | 2.800 Teilnehmende gesucht |
Sponsor und Mitwirkende
- AstraZeneca Sponsor
Studienarme und Interventionen
- Balcinrenone/dapagliflozinEXPERIMENTAL
Patient receives once daily 1 capsule balcinrenone 15 mg and dapagliflozin 10 mg and 1 placebo tablet matching dapagliflozin.
- DapagliflozinACTIVE_COMPARATOR
Patient receives once daily 1 placebo capsule matching balcinrenone and dapagliflozin and 1 tablet dapagliflozin 10 mg.
Interventionen
- Arzneimittel Balcinrenone/dapagliflozin
balcinrenone/dapagliflozin 15 mg/10 mg
- Arzneimittel Dapagliflozin
dapagliflozin 10 mg
- Arzneimittel Placebo matching Dapagliflozin
matching placebo for dapagliflozin 10 mg
- Arzneimittel Placebo matching balcinrenone/dapagliflozin
matching placebo for balcinrenone/dapagliflozin
Endpunkte
Primärer Endpunkt
Time to first occurrence of cardiovascular death, death from kidney failure, kidney failure, sustained 50% or greater decline in eGFR, and heart failure event
Time from randomization to first occurrence of any of the components of the composite: * CV death * Death from kidney failure * Onset of kidney failure * Initiation of maintenance dialysis or * Kidney transplantation * Sustained ≥ 50% decline from baseline in eGFR * HF with or without hospitalisation
Zeitrahmen Up to 46 months.
Sekundärer Endpunkt
Time to first occurrence of cardiovascular death, death from kidney failure, kidney failure and sustained 50% or greater decline in eGFR.
Time from randomization to first occurrence of any of the components of the composite: * CV death * Death from kidney failure * Onset of kidney failure: * Initiation of maintenance dialysis or * Kidney transplantation Sustained ≥ 50% decline from baseline in eGFR
Zeitrahmen Up to 46 months.
Sekundärer Endpunkt
Change in urinary albumin to creatinine ratio to Week 24
Change from baseline to Week 24 in urinary albumin to creatinine ratio
Zeitrahmen Baseline to Week 24
Sekundärer Endpunkt
Time to first occurrence of cardiovascular death or heart failure event.
Time from randomization to first occurrence of any of the components of the composite: * CV death * HF with or without hospitalisation
Zeitrahmen Up to 46 months.
Sekundärer Endpunkt
Time to cardiovascular death
Time from randomization to cardiovascular death.
Zeitrahmen Up to 46 months.
Sekundärer Endpunkt
Time to death from any cause
Time from randomization to death from any cause.
Zeitrahmen Up to 46 months.
Daten
| Startdatum | 1. September 2026 (tatsächlich) |
|---|---|
| Primärer Abschluss | 1. Juli 2030 (geschätzt) |
| Abschluss | 1. Juli 2030 (geschätzt) |
| Erstveröffentlichung | 3. Juni 2026 (tatsächlich) |
| Zuletzt aktualisiert | 24. September 2026 |
| Ergebnisse veröffentlicht | Im Registereintrag nicht angegeben |
| Status zuletzt bestätigt | September 2026 |
Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.
Standorte
33 Studienzentren rekrutieren
Argentina
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Research Site | CABA | Rekrutierung noch nicht begonnen | |
| Research Site | Capital Federal | Rekrutierung noch nicht begonnen | |
| Research Site | Ciudad de Buenos Aires | Rekrutierung noch nicht begonnen | |
| Research Site | La Plata | Rekrutierung noch nicht begonnen | |
| Research Site | Lanús Este | Rekrutierung noch nicht begonnen | |
| Research Site | Mar del Plata | Rekrutierung noch nicht begonnen | |
| Research Site | Rosario | Rekrutierung noch nicht begonnen | |
| Research Site | Rosario | Rekrutierung noch nicht begonnen | |
| Research Site | Rosario | Rekrutierung noch nicht begonnen | |
| Research Site | San Nicolás | Rekrutierung noch nicht begonnen | |
| Research Site | Santa Fe | Rekrutierung noch nicht begonnen | |
| Research Site | Santa Fe | Rekrutierung noch nicht begonnen |
Austria
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Research Site | Feldkirch | Rekrutierung noch nicht begonnen | |
| Research Site | Innsbruck | Rekrutierung noch nicht begonnen | |
| Research Site | Linz | Rekrutierung noch nicht begonnen | |
| Research Site | Sankt Pölten | Rekrutierung noch nicht begonnen | |
| Research Site | Vienna | Rekrutierung noch nicht begonnen | |
| Research Site | Vienna | Rekrutierung noch nicht begonnen | |
| Research Site | Vienna | Rekrutierung noch nicht begonnen | |
| Research Site | Vienna | Rekrutierung noch nicht begonnen | |
| Research Site | Wels | Rekrutierung noch nicht begonnen | |
| Research Site | Wiener Neustadt | Rekrutierung noch nicht begonnen |
Brazil
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Research Site | Barretos | Rekrutierung noch nicht begonnen | |
| Research Site | Belo Horizonte | Rekrutierung noch nicht begonnen | |
| Research Site | Belo Horizonte | Rekrutierung noch nicht begonnen | |
| Research Site | Belém | Rekrutierung noch nicht begonnen | |
| Research Site | Campinas | Rekrutierung noch nicht begonnen | |
| Research Site | Goiânia | Rekrutierung noch nicht begonnen | |
| Research Site | Natal | Rekrutierung noch nicht begonnen | |
| Research Site | Recife | Rekrutierung noch nicht begonnen | |
| Research Site | São Caetano do Sul | Rekrutierung noch nicht begonnen | |
| Research Site | São José do Rio Preto | Rekrutierung noch nicht begonnen | |
| Research Site | São José dos Campos | Rekrutierung noch nicht begonnen | |
| Research Site | São Paulo | Rekrutierung noch nicht begonnen | |
| Research Site | São Paulo | Rekrutierung noch nicht begonnen | |
| Research Site | São Paulo | Rekrutierung noch nicht begonnen | |
| Research Site | São Paulo | Rekrutierung noch nicht begonnen |
Bulgaria
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Research Site | Blagoevgrad | Rekrutierung noch nicht begonnen | |
| Research Site | Nova Zagora | Rekrutierung noch nicht begonnen | |
| Research Site | Pleven | Rekrutierung noch nicht begonnen | |
| Research Site | Plovdiv | Rekrutierung noch nicht begonnen | |
| Research Site | Sandanski | Rekrutierung noch nicht begonnen | |
| Research Site | Sevlievo | Rekrutierung noch nicht begonnen | |
| Research Site | Sofia | Rekrutierung noch nicht begonnen | |
| Research Site | Sofia | Rekrutierung noch nicht begonnen | |
| Research Site | Sofia | Rekrutierung noch nicht begonnen | |
| Research Site | Stara Zagora | Rekrutierung noch nicht begonnen | |
| Research Site | Varna | Rekrutierung noch nicht begonnen |
Canada
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Research Site | Brampton | Ontario | Rekrutierung noch nicht begonnen |
| Research Site | Calgary | Alberta | Zurückgezogen |
428 weitere Studienzentren sind im Registereintrag aufgeführt.
Studiendokumente
In diesem Registereintrag sind keine Dokumente verlinkt.
Änderungen im Zeitverlauf
- 24. September 2026
Status geändert
Status changed from Not yet recruiting to Recruiting
NOT_YET_RECRUITINGRECRUITING
- 24. September 2026
Rekrutierung eröffnet
Recruitment opened
NOT_YET_RECRUITINGRECRUITING
- 24. September 2026
Studienzentrum hinzugefügt
433 sites added (478 total)
45478